21.50GBp+7.50%Mkt Cap: 29.10M GBpP/E: —Last update: 2026-05-13
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a T…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-0.06
PEG—
P/B23.33
P/S—
EV/EBITDA—
EV/Revenue—
EPS (TTM)-0.04
EPS (Forward)-3.60
Cash Flow & Leverage
FCF Yield-3.22%
FCF Margin—
Operating CF-2.55M GBp
CapEx (TTM)—
Net Debt/EBITDA—
Net Debt-2.49M GBp
Technical
SMA 5018.02 (+19.3%)
SMA 20017.97 (+19.6%)
Beta-0.81
S&P 52W Chg24.23%
Avg Vol (30d)230.56K
Avg Vol (10d)165.68K
Technical Indicators
RSI (14)71.2
MACD0.8658
MACD Signal1.0251
MACD Hist.-0.1593
BB Upper22.63 GBp
BB Middle20.48 GBp
BB Lower18.32 GBp
BB Width21.08%
ATR (14)1.561 GBp
Vol Ratio (20d)1.53x
52W Range
9.50062% of range29.00
52W High29.00 GBp
52W Low9.500 GBp
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-194.91%
ROA-104.92%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio1.58
Quick Ratio1.58
Book Value/Sh0.0090 GBp
Cash/Share0.0180 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMar 1, 2022
Ownership
Shares Out.138.57M
Float132.28M
Insiders6.49%
Institutions0.00%
Analyst Consensus
Rating—
Target (Mean)41.60 GBp
Target Range41.60 GBp – 41.60 GBp
# Analysts1
Company
Market Cap29.10M GBp
Enterprise Value26.43M GBp
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.44M GBp
Revenue/Share—
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees5
Last Price21.50 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINJP3399310006